Time to absolute neutrophil and platelet counts and treatment-related mortality after allogeneic PBSCT or BMT
| Study . | Study design, donor-recipient relationship . | No. patients . | Median days to ANC > 0.5 × 109/L . | Median days to platelet > 20 × 109/L . | Transplant-related mortality rates . | |||
|---|---|---|---|---|---|---|---|---|
| BM . | PBSC . | BM . | PBSC . | BM (%) . | PBSC (%) . | |||
| Vigorito et al38 | Randomized, related | 37 | 18 | 16 | 17 | 12 | 77.8 (median FU, 631 d) | 62.5 (median FU, 335 d) |
| Blaise et al39 | Randomized, related | 101 | 21 | 15 | 21 (> 25 × 109/L) | 13 (> 25 × 109/L) | 21 (at d 180) | 23 (at d 180) |
| Ringden et al40 | Matched-pair, unrelated | 90 | 20 | 16 | 29 (> 50 × 109/L) | 23 (> 50 × 109/L) | 21 (at 1 y) | 27 (at 1 y) |
| Heldal et al41 | Randomized, related | 61 | 23 | 17 | 21 | 13 | 0 (at d 100) 10 (at 1 y) | 13 (at d 100) 17 (at 1 y) |
| Powles et al42 | Randomized, related | 39 | 23 | 17.5 | 18 | 11 | 31 (median FU, 57 d) | 35 (median FU, 57 d) |
| Schmitz et al43 | Randomized, related | 350 | 15 | 12 | 20 | 15 | No significant difference | No significant difference |
| Simpson et al44 | Randomized, related | 228 | 22 | 19 | 22 | 16 | 164-150 (at d 100) | 7.54-150 (at d 100) |
| Champlin et al45 | Retrospective registry analysis, related | 824 | 19 | 14 | 25 | 18 | 28 (AL CR1) 30 (AL CR2)4-150 27 (CML CP1) 67 (CML AP/CP2)4-150(at 1 y) | 18 (AL CR1) 13 (AL CR2)4-150 37 (CML CP1) 26 (CML AP/CP2)4-150 (at 1 y) |
| Bensinger et al10 | Randomized, related | 172 | 21 | 16 | 19 | 13 | 30 (at 2 y) | 21 (at 2 y) |
| Study . | Study design, donor-recipient relationship . | No. patients . | Median days to ANC > 0.5 × 109/L . | Median days to platelet > 20 × 109/L . | Transplant-related mortality rates . | |||
|---|---|---|---|---|---|---|---|---|
| BM . | PBSC . | BM . | PBSC . | BM (%) . | PBSC (%) . | |||
| Vigorito et al38 | Randomized, related | 37 | 18 | 16 | 17 | 12 | 77.8 (median FU, 631 d) | 62.5 (median FU, 335 d) |
| Blaise et al39 | Randomized, related | 101 | 21 | 15 | 21 (> 25 × 109/L) | 13 (> 25 × 109/L) | 21 (at d 180) | 23 (at d 180) |
| Ringden et al40 | Matched-pair, unrelated | 90 | 20 | 16 | 29 (> 50 × 109/L) | 23 (> 50 × 109/L) | 21 (at 1 y) | 27 (at 1 y) |
| Heldal et al41 | Randomized, related | 61 | 23 | 17 | 21 | 13 | 0 (at d 100) 10 (at 1 y) | 13 (at d 100) 17 (at 1 y) |
| Powles et al42 | Randomized, related | 39 | 23 | 17.5 | 18 | 11 | 31 (median FU, 57 d) | 35 (median FU, 57 d) |
| Schmitz et al43 | Randomized, related | 350 | 15 | 12 | 20 | 15 | No significant difference | No significant difference |
| Simpson et al44 | Randomized, related | 228 | 22 | 19 | 22 | 16 | 164-150 (at d 100) | 7.54-150 (at d 100) |
| Champlin et al45 | Retrospective registry analysis, related | 824 | 19 | 14 | 25 | 18 | 28 (AL CR1) 30 (AL CR2)4-150 27 (CML CP1) 67 (CML AP/CP2)4-150(at 1 y) | 18 (AL CR1) 13 (AL CR2)4-150 37 (CML CP1) 26 (CML AP/CP2)4-150 (at 1 y) |
| Bensinger et al10 | Randomized, related | 172 | 21 | 16 | 19 | 13 | 30 (at 2 y) | 21 (at 2 y) |
AL indicates acute leukemia; CML, chronic myelogenous leukemia; CR, complete remission; CP, chronic phase; AP, accelerated phase; FU, follow-up.
Statistically significant.